Research map: DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives

Back to the article

Papers in this map

  1. Cancer statistics, 2025 · Rebecca L. Siegel · 2025 · 2992 citations · Cited by this paper
  2. Sibeprenlimab: First Approval · 2026 · Related
  3. Notch signaling pathway: architecture, disease, and therapeutics · Binghan Zhou · 2022 · 1132 citations · Cited by this paper
  4. The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir · 2026 · Related
  5. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms · Guido Rindi · 2022 · 1032 citations · Cited by this paper
  6. Ecnoglutide: First Approvals · 2026 · Related
  7. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours · Holger Moch · 2022 · 884 citations · Cited by this paper
  8. DLL3 Expression in Neuroendocrine Carcinomas and Neuroendocrine Tumours: Insights From a Multicentric Cohort of 1294 Pulmonary and Extrapulmonary Neuroendocrine Neoplasms · 2025 · Related
  9. The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide · Adalberto Miranda‐Filho · 2024 · 877 citations · Cited by this paper
  10. Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering · 2026 · Related
  11. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study · Rahul Raj Aggarwal · 2018 · 853 citations · Cited by this paper
  12. Etripamil: First Approval · 2026 · Related
  13. The Lancet Commission on prostate cancer: planning for the surge in cases · Nicholas David James · 2024 · 726 citations · Cited by this paper
  14. Long-Acting Lipoglycopeptide Treatment of Invasive Gram-Positive Infections · 2026 · Related
  15. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo · Laura R. Saunders · 2015 · 606 citations · Cited by this paper
  16. Emerging Cardiorenal Protective Therapies in Lupus Nephritis · 2026 · Related
  17. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer · Myung‐Ju Ahn · 2023 · 580 citations · Cited by this paper
  18. Expression of DLL3 and SEZ6 in the Spectrum of Neuroendocrine Neoplasia · 2025 · Related
  19. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer · Jennifer L. Bishop · 2016 · 453 citations · Cited by this paper
  20. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability · Toan Duc Nguyen · 2023 · 425 citations · Cited by this paper
  21. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance · Himisha Beltran · 2019 · 420 citations · Cited by this paper
  22. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study · Luis G Paz-Ares · 2023 · 338 citations · Cited by this paper
  23. Clinical and Biological Features of Neuroendocrine Prostate Cancer · Yasutaka Yamada · 2021 · 327 citations · Cited by this paper
  24. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling · Lauren Brady · 2021 · 308 citations · Cited by this paper
  25. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers · Ana Maria Aparicio · 2015 · 302 citations · Cited by this paper
  26. The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands · Ena Ladi · 2005 · 283 citations · Cited by this paper
  27. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy · Giannis Mountzios · 2025 · 272 citations · Cited by this paper
  28. DLL3: an emerging target in small cell lung cancer · Dwight Hall Owen · 2019 · 243 citations · Cited by this paper
  29. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer · Loredana Puca · 2019 · 219 citations · Cited by this paper
  30. Emerging Variants of Castration-Resistant Prostate Cancer · Panagiotis J. Vlachostergios · 2017 · 199 citations · Cited by this paper
  31. Molecular events in neuroendocrine prostate cancer development · Yong Wang · 2021 · 199 citations · Cited by this paper
  32. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer · Charles M. Rudin · 2023 · 182 citations · Cited by this paper
  33. Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer · Yanhua Tian · 2022 · 156 citations · Cited by this paper
  34. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy · Lara L. Riegler · 2019 · 142 citations · Cited by this paper
  35. Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology · Daniel Eidelberg Spratt · 2025 · 114 citations · Cited by this paper
  36. Neuroendocrine and Aggressive-Variant Prostate Cancer · Nicholas Spetsieris · 2020 · 111 citations · Cited by this paper
  37. Therapy considerations in neuroendocrine prostate cancer: what next? · Himisha Beltran · 2021 · 98 citations · Cited by this paper
  38. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms · James C. Yao · 2022 · 97 citations · Cited by this paper
  39. International real-world study of DLL3 expression in patients with small cell lung cancer · Federico Rojo · 2020 · 90 citations · Cited by this paper

Source: OpenAlex (CC0)